Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$22.97
-2.9%
$20.81
$10.96
$24.13
$1.19B2.49705,810 shs769,115 shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$17.14
-3.3%
$15.35
$10.28
$26.92
$1.02BN/A956,994 shs672,186 shs
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$32.85
+0.2%
$32.27
$21.73
$37.54
$1.14B1.29228,344 shs321,128 shs
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$2.87
-4.0%
$3.46
$2.78
$5.75
$294.40M0.59118,387 shs86,387 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-2.92%+3.24%+11.45%+35.04%+14.39%
Omada Health, Inc. stock logo
OMDA
Omada Health
-3.33%-4.41%+6.86%+17.96%+1,713,999,900.00%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
+0.21%+3.60%-7.70%-0.12%+18.81%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
-4.01%-4.65%-11.15%-19.38%-38.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$22.97
-2.9%
$20.81
$10.96
$24.13
$1.19B2.49705,810 shs769,115 shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$17.14
-3.3%
$15.35
$10.28
$26.92
$1.02BN/A956,994 shs672,186 shs
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$32.85
+0.2%
$32.27
$21.73
$37.54
$1.14B1.29228,344 shs321,128 shs
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$2.87
-4.0%
$3.46
$2.78
$5.75
$294.40M0.59118,387 shs86,387 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-2.92%+3.24%+11.45%+35.04%+14.39%
Omada Health, Inc. stock logo
OMDA
Omada Health
-3.33%-4.41%+6.86%+17.96%+1,713,999,900.00%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
+0.21%+3.60%-7.70%-0.12%+18.81%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
-4.01%-4.65%-11.15%-19.38%-38.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.00
Hold$25.008.84% Upside
Omada Health, Inc. stock logo
OMDA
Omada Health
2.69
Moderate Buy$22.9133.66% Upside
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
2.88
Moderate Buy$39.0018.72% Upside
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
2.33
Hold$8.50196.17% Upside

Current Analyst Ratings Breakdown

Latest SBC, CDNA, PNTG, and OMDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingSell (E+)
5/27/2026
CareDx, Inc. stock logo
CDNA
CareDx
Reiterated RatingSell (D)
5/22/2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
UpgradeHold (C+)Buy (B-)
5/22/2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
DowngradeHold (C-)Sell (D+)
5/8/2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
UpgradeSell (D+)Hold (C-)
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingBuy
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingOutperform$20.00
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Set Price Target$24.00
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Reiterated RatingOutperform
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetOverweight$18.00 ➝ $20.00
5/8/2026
Omada Health, Inc. stock logo
OMDA
Omada Health
Boost Price TargetMarket Outperform$18.00 ➝ $21.00
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M3.12$0.01 per share3,632.51$5.89 per share3.90
Omada Health, Inc. stock logo
OMDA
Omada Health
$260.21M3.92N/AN/A$3.97 per share4.32
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$947.71M1.21$1.28 per share25.58$10.82 per share3.04
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$173.61M1.70$0.50 per share5.71$2.57 per share1.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M-$0.16N/A76.57N/A-2.01%-2.65%-1.96%8/5/2026 (Estimated)
Omada Health, Inc. stock logo
OMDA
Omada Health
-$12.78M-$0.27N/A122.43N/A-2.22%-1.82%-1.36%N/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$29.58M$0.8538.6524.512.202.96%10.07%4.23%8/5/2026 (Estimated)
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$50.99M$0.397.365.86N/A24.09%15.90%11.61%8/12/2026 (Estimated)

Latest SBC, CDNA, PNTG, and OMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$0.10$0.11+$0.01$0.11$41.66 million$43.06 million
5/7/2026Q1 2026
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.08-$0.05+$0.03-$0.05N/A$78.05 million
5/6/2026Q1 2026
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$0.31$0.32+$0.01$0.24$280.75 million$285.36 million
4/28/2026Q1 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.11$0.34+$0.23$0.05$102.03 million$117.70 million
3/27/2026Q4 2025
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
$0.13$0.14+$0.01$0.14$45.19 million$39.57 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
N/AN/AN/AN/AN/A
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
3.40
3.07
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
3.92
3.87
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
0.42
1.19
1.19
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
0.12
3.82
3.78

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
85.88%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
60.82%

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
Omada Health, Inc. stock logo
OMDA
Omada Health
6.38%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
6.90%
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
81.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
74051.66 million50.42 millionOptionable
Omada Health, Inc. stock logo
OMDA
Omada Health
84959.45 million55.66 millionN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
9,70034.77 million32.37 millionOptionable
SBC Medical Group Holdings Incorporated stock logo
SBC
SBC Medical Group
N/A102.58 million18.77 millionN/A

Recent News About These Companies

SBC Medical Group (NASDAQ:SBC) Shares Down 4% - Here's Why
SBC Medical Group Q1 Earnings Call Highlights
SBC Medical to Announce 1Q 2026 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

CareDx stock logo

CareDx NASDAQ:CDNA

$22.97 -0.69 (-2.92%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$23.14 +0.17 (+0.74%)
As of 06/12/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Omada Health stock logo

Omada Health NASDAQ:OMDA

$17.14 -0.59 (-3.33%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$17.14 0.00 (0.00%)
As of 06/12/2026 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

The Pennant Group stock logo

The Pennant Group NASDAQ:PNTG

$32.85 +0.07 (+0.21%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$32.86 +0.01 (+0.03%)
As of 06/12/2026 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

SBC Medical Group stock logo

SBC Medical Group NASDAQ:SBC

$2.87 -0.12 (-4.01%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$3.04 +0.17 (+5.92%)
As of 06/12/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.